ACRV Latest Press Releases

-- August 12, 2026 --

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts Globe Newswire 4:05 PM

-- August 5, 2026 --

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study Globe Newswire 8:30 AM

-- July 21, 2026 --

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference Globe Newswire 4:30 PM

-- May 21, 2026 --

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit Globe Newswire 7:30 AM

-- May 15, 2026 --

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- May 13, 2026 --

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts Globe Newswire 4:10 PM

-- April 17, 2026 --

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities Globe Newswire 4:00 PM

-- April 15, 2026 --

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software